Modality
mRNA
MOA
BTKi
Target
FXIa
Pathway
Fibrosis
MS
Development Pipeline
Preclinical
~Sep 2020
→ ~Dec 2021
Phase 1
~Mar 2022
→ ~Jun 2023
Phase 2
~Sep 2023
→ ~Dec 2024
Phase 3
Mar 2025
→ Mar 2026
Phase 3Current
NCT06352359
779 pts·MS
2025-03→2026-03·Not yet recruiting
779 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-03-274d agoPh3 Readout· MS
Trial Timeline
Q2Q3Q42026Q2
P3
Not yet…
Catalysts
Ph3 Readout
2026-03-27 · 4d ago
MS
Not yet recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06352359 | Phase 3 | MS | Not yet recr... | 779 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| RHH-682 | Roche | Phase 2 | FXIa | |
| RHH-7975 | Roche | Phase 3 | FXIa | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| NVO-6275 | Novo Nordisk | Phase 1 | SMN2 | |
| Zanumavacamten | GSK | Phase 2/3 | TROP-2 |